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Abstract:
Weighing up sources of evidence is a key skill for clinical decision-
makers.  Randomised controlled trials (RCTs) and observational studies 
each have advantages and disadvantages, and in both cases perceived 
weaknesses can be improved through modifications of design and 
analysis. In the field of pharmacoepidemiology, RCTs provide better 
evidence than observational studies, largely because randomisation 
reduces bias and confounding. Although observational studies, even in a 
small cohort, can provide very useful clinical evidence, they may also be 
misleading (as shown by subsequent RCTs), in part because of allocation 
bias. There is an unmet need for clinicians to become well-versed in 
appraising the study design and statistical analysis of observational 
pharmacoepidemiology (OP) studies, rather like the medical training 
already offered for RCT evaluation. This is because OP studies are likely 
to become more common with the computerisation of healthcare records 
and increasingly contribute to the evidence base available for clinical 
decision-making. However, when the results of an RCT onflict with the 
results of an OP study, the findings of the RCT should be preferred, 
especially if its findings have been repeated elsewhere. Conversely, OP 
studies that align with the findings of RCTs can provide rich and useful 
information to complement that generated by RCTs. 
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35 Abstract
36 Weighing up sources of evidence is a key skill for clinical decision-makers.  Randomised 37 controlled trials (RCTs) and observational studies each have advantages and disadvantages, and 38 in both cases perceived weaknesses can be improved through modifications of design and 39 analysis. In the field of pharmacoepidemiology, RCTs provide better evidence than 40 observational studies, largely because randomisation reduces bias and confounding. Although 41 observational studies, even in a small cohort, can provide very useful clinical evidence, they may 42 also be misleading (as shown by subsequent RCTs), in part because of allocation bias. There is 43 an unmet need for clinicians to become well-versed in appraising the study design and 44 statistical analysis of observational pharmacoepidemiology (OP) studies, rather like the medical 45 training already offered for RCT evaluation. This is because OP studies are likely to become 46 more common with the computerisation of healthcare records and increasingly contribute to 47 the evidence base available for clinical decis on-making. However, when the results of an RCT 48 conflict with the results of an OP study, the findings of the RCT should be preferred, especially if 49 its findings have been repeated elsewhere. Conversely, OP studies that align with the findings of 50 RCTs can provide rich and useful information to complement that generated by RCTs. 
51
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52 Introduction
53 Robust evidence about clinical interventions is necessary for many reasons, from the licensing 54 of new treatments to informing clinical practice, guideline creation and clinical/cost 55 effectiveness analysis. Pharmacoepidemiology involves the study of drug-based interventions in 56 populations and for more than 70 years the randomised controlled trial (RCT) has been the 57 mainstay of this field. RCTs differ from observational pharmacoepidemiology (OP) studies in 58 one key way – the random assignment of participants to interventions. Randomisation serves to 59 ensure that confounders and effect modifiers are randomly allocated between the groups, thus 60 providing unbiased estimates of treatment effect.  For this reason, they are the preferred 61 approach for estimating relative and absolute treatment effects and therefore are more useful in 62 supporting clinical decision-making.  RCTs are most impactful from the epidemiological 63 perspective where efforts have been made to increase their generalisability.
64 Observational studies have also provided valuable evidence in the field of medicine. They 65 demonstrated the benefits of treating diabetes with insulin and the link between smoking and 66 lung cancer, for example.1,2 Indeed, observational studies remain universally accepted for 67 delineating the natural history of diseases, their risk factors and prognostic markers. However, 68 observational pharmacoepidemiology, where (beneficial/harmful) treatment effects are 69 quantified, has been subject to criticism. This is because bias and confounding create difficulty 70 in attributing cause and effect. It remains the case, however, that OP studies remain the 71 mainstay of pharmacovigilance for harmful effects once a drug has been licensed. 
72 A false ‘conflict’ between proponents of RCTs and OP studies has been created. Both types of 73 study have important, often complementary, objectives and each can help deliver evidence not 74 supplied by the other. Also, both RCTs and OP studies have their strengths and weaknesses and 75 can provide flawed answers, through poor design, execution or analysis. Furthermore, there is 76 increasing concern about the observed efficacy-effectiveness gap, which is the inconsistency 77 between the effects of an intervention reported in clinical trials compared to that reported in 
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78 routine clinical practice. It is likely that well-designed OP studies (alongside more generalisable 79 RCTs) will help to plug this gap.3
80 Well-designed and well-conducted RCTs have good internal validity, which in turn allows 81 inferences on (relative) efficacy and causality to be made.4 Efficacy is described as ‘the 82 performance of an intervention under ideal, controlled circumstances compared to placebo’ 83 whereas relative efficacy is similar to this except comparison is to a standard alternative rather 84 than placebo. Relative effectiveness is described as an intervention’s performance in a ‘variety of 85 endpoints important to patients and healthcare providers compared to the usual care offered by 86 a health system in the population of patients identified as eligible for treatment by their care 87 providers, subject  to free and variable patient and clinician behaviour’ and can be measured in 88 pragmatic RCTs or in OP studies.3,5  
89 Weighing-up clinical evidence is a key skill for clinical decision-making.  The Academy of 90 Medical Sciences has recently published an extensive report on the ‘sources of evidence for 91 assessing the safety, efficacy and effectiveness of medicines’.6 In this article, we discuss the 92 inherent properties, advantages and disadvantages of both type of study and how they might be 93 improved. This will assist readers in balancing evidence to make clinical decisions, particularly 94 in the field of OP, where robust methodology and statistical analysis is less well-understood. 95 However, we argue that when the results of RCTs and OP studies in similar patient populations 96 are conflicting, the results of a well-designed and executed RCT are more likely to represent an 97 unbiased estimate of the treatment effect. However, well-designed and executed OP studies can 98 confirm and extend the findings of RCTs and show that treatment works in groups often 99 excluded from RCTs, such as older people, the very young and those with comorbidities. 
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100 Randomised controlled trials in pharmacoepidemiology
101 The inherent properties of RCTs make them the most robust means of evaluating healthcare 102 interventions (see table 1 for brief description of study types).4 When properly designed and 103 executed, with sufficient power and appropriate analysis, RCTs give the best indication of the 104 efficacy of an intervention.4 The key properties of RCTs that differ from OP studies are:
105  A pre-planned experiment, which gives rise to internal validity (and can reduce 106 selection bias)107  Random allocation to treatment, which prevents allocation bias (also variously known 108 as channelling bias, contraindication bias, confounding by indication, confounding by 109 severity or confounding by frailty)110  Blinding, which avoids observer bias (although some RCTs are not blinded)
111 The advantages of RCTs stem from:
112  The reduction of bias and the equal distribution of confounders and effect modifiers 113 provided by randomisation114  Blinding, when done, reduces observer bias and contamination of result reporting by 115 patients knowing which intervention they have received, particularly when outcomes 116 are subjective117  Formal calculation of adequate trial size to ensure satisfactory study power and thus 118 meaningful results 119  The minimisation of missing data and the systematic collection of outcomes to prevent 120 information bias (see table 2 for a description of biases and their mitigation)
121 An effect modifier is a clinical characteristic (e.g. age, sex, genotype etc.) which causes the effect 122 of the exposure to change (e.g. hormone replacement therapy’s protection from endometrial 123 cancer only appears to operate in women with a body mass index (BMI) >30, thus in this context 124 BMI can be considered an effect modifier).7 Bradford Hill lists a number of criteria that increase 
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125 confidence that an association is causal (see table 3 for these criteria as applied to the medical 126 sciences). He states that ‘experimentation’ lends the strongest support to causality – the design 127 of RCTs can fulfil the experimentation criterion and support causal inferences.8 
128 RCTs also have limitations, assuming otherwise robust design. These relate particularly to the 129 generalisability of results (i.e. who gets selected for inclusion in the study and whether they are 130 representative of the population to whom the results will be applied). Other limitations of RCTs 131 relate to the length of follow-up, which when long can dramatically increase costs, and trial size, 132 which can also increases costs and when inadequate can mean insufficient power of the trial to 133 detect treatment effect and, more commonly, rare safety event outcomes. 
134  If an RCT is improperly designed, performed or analysed it may mislead more than a well-135 designed OP study that attempts to account for bias and confounding.9 In the following sections 136 the characteristics of RCTs in pharmacoepidemiology and strategies to ensure their good 137 conduct are addressed in more detail.
138
139 The advantage of randomisation, allocation concealment and blinding 140
141 Randomisation is a major contributor to the benefit RCTs have over observational studies. The 142 random allocation of participants to treatment groups achieves comparability between these, 143 especially in terms of prior risk of the outcome of interest and any effect modifiers (see table 2 144 for a brief overview of biases and their mitigation). This allows causal inferences to be made; in 145 other words, the treatment effect observed is likely due to the intervention, all things being 146 equal. If certain co-variates might not be equally distributed between treatment groups with 147 patient-level randomisation then stratified randomisation might be employed to improve group 148 comparability, e.g. it might be important there be equal numbers of patients with a rare, severe 149 disease phenotype in both arms.10 In either case, whether using stratified or patient-level 150 randomisation, any increase in comparability applies equally to variables we can and cannot 
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151 measure,  reducing or balancing confounders and effect modifiers.10–12 It is essential that the 152 randomisation process is not compromised, which is achieved through robust randomisation 153 methods and allocation concealment.9 
154 Importantly, allocation concealment and blinding of allocation are not the same. The former 155 means hiding the sequence of allocation prior to recruitment, so it is not possible to predict to 156 which treatment group a participant will be assigned.13 Blinding is the process of continuing 157 allocation concealment until the end of the study and is easier to do in RCTs than other types of 158 epidemiological study.14 The effect of blinding is to reduce observer bias in ascertaining the 159 outcomes of interest, a form of differential information bias (see table 2, for a more in depth 160 description of information bias).15 . Ideally, all participants and staff ought to be blinded, but this 161 is not always practicable.15,16 In RCTs, although blinding requires allocation concealment, 162 allocation concealment is not always followed by blinding. When allocation concealment is 163 undertaken but the study is not blinded, a trial is said to be open-label. 
164 Open-label studies are thought to increase the risk of observer bias. To minimise this, in open-165 label studies, staff analysing the outcome data should be blinded to allocation, as this is almost 166 always possible, and is particularly important when the outcome is subjective.13 
167 PROBE: A particular type of open-label study design, the Prospective Randomised Open Blinded 168 End-point study has been proposed, thought to be more cost-effective than the double blind 169 prospective study. The study design uses strict randomisation and hard end-point definitions 170 (ones that are well-defined and measured objectively) to allow for the comparison of 171 interventions to take place. Outcome data are collected through routine clinical care which may 172 increase the generalisability of PROBE study findings. However, the open-label nature of the 173 trial may introduce observer bias (a type of information bias) in the recording of the end-point, 174 even though the use of hard end-points tries to reduce this possibility.  Also patients know 175 which intervention they are exposed to, which introduces the risk of contamination if they seek 176 a different treatment from another healthcare provider that goes unrecorded in the trial.17 
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177
178 Reduction of bias and confounding in RCTs compared to OP studies179
180 Bias is ‘a systematic (as opposed to random) distortion, due to a design flaw, interfering factor 181 or judgement that can affect the conception, design or conduct of a study or the collection, 182 analysis, interpretation, presentation or discussion of outcome data, causing erroneous over-183 /under-estimation of the probable size or direction of a treatment effect or association’.18,19 
184 Confounders  are extraneous factors directly, or inversely, associated with the variables being 185 measured such that it creates the false impression of an association between the variables 186 which, were it not for the confounder, does not exist.20. Confounders differ from biases in that, if 187 the confounder is known, statistical methods can be employed to adjust for its effect at the 188 analysis stage, which is not always the case with bias as it cannot be corrected for once 189 introduced into a study.21 It is of course, not possible to correct for unknown confounders. 190 Spurious associations are associations that are not real and occur due to chance and bias. 191 Indirect associations are real but not causal and stem from confounding.
192 The design of RCTs can significantly reduce both bias and confounding and hence spurious and 193 indirect associations. In the main, there are three categories of bias which the design of an RCT 194 minimises (indeed most biases fit into one of these broad categories, despite their varying 195 nomenclature); selection bias, allocation bias and information bias. In selection bias there are 196 systematic differences between those who are observed (included) in a study compared to those 197 who are not, particularly in terms of prior risk of the outcome of interest or effect modifiers. 198 This means that the population under study is no longer representative of the condition being 199 investigated and participants differ from the population to whom the results are to be applied 200 independently of the interventions being studied.  Allocation bias occurs when there are 201 systematic differences between how participants are assigned to their treatment group, meaning 202 that those exposed to an intervention differ from those not exposed in terms of their prior risk 
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203 of the outcome of interest or effect modifiers. Information bias occurs when information is 204 obtained differently (for whatever reason) between the groups such as a flaw in measuring 205 exposure, outcomes or co-variates with differing accuracy, intentionally or unintentionally. See 206 table 2 for more information about biases and their mitigation. Randomisation, with a large 207 enough sample, operates to reduce confounding and differential effect modification, by 208 balancing these between the groups.20 
209 The Cochrane Handbook for Systematic Review of Interventions contains a tool which uses 210 readers’ judgement for assessing the risk of bias in a study, hence making a verdict about its 211 internal validity and in turn whether the study merits inclusion in a systematic review.22 In 212 order to maintain the benefits inherent to RCTs and provide for adequate reporting of protocols 213 and results, the following paragraphs describe agreed reporting standards. 
214 CONSORT: The CONsolidated Standards Of Reporting Trials 23 aims ‘to alleviate the problems 215 arising from the inadequate reporting of RCTs’. It consists of an evidence-based minimum 216 standard of recommendations to assist with complete and transparent reporting of RCTs, 217 thereby aiding critical appraisal and interpretation. Since its inception in 1993, CONSORT has 218 undergone regular revisions; the current 2010 revision consists of a 25-item checklist and 219 flowchart focussing on how the trial was designed, analysed and interpreted; a central tenet is 220 the pre-registration of trial protocols. In particular, adherence to CONSORT may reduce 221 selective reporting bias (a type of information bias) and allows the reader to ascertain whether 222 included analyses were pre-planned or not and, if not, to offer an explanation as to why the 223 analysis became necessary. A number of studies have investigated the effect of the 2001 224 revision to the CONSORT guidelines on the completeness of reporting.24–26 Although these found 225 that there was a general trend of improvement in the reporting of important aspects of trial 226 methodology, it remained sub-optimal.24–26 Endorsement of CONSORT by journals may 227 beneficially influence the completeness of trial reporting in the medical literature.24 
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228 Statistical analysis plan (SAP): this is a critical document to the undertaking of RCTs (and indeed 229 OP studies) and making the plan available supports transparency and reproducibility, especially 230 since statistical decisions carry great weight for the conclusions of a trial. SAP is a ‘more detailed 231 and technical elaboration of the principle features of analysis included in the trial protocol’27. 232 However, until recently (2017) no guidance existed for SAP contents (compare with CONSORT 233 which has existed since 1993). A recently published expert consensus document has now 234 specified minimum content for SAP in relation to RCTs28 (and also now exists for OP studies29). 235 It will be important to measure whether this guideline improves the transparency of reporting 236 of statistical analysis and consequently whether this improves the reproducibility of RCTs (and 237 OP studies). 
238
239 RCTs have internal validity, which allows causality to be established240
241 Well-designed and well-conducted RCTs have internal validity, which is the extent to which 242 causal conclusions regarding a study are justified.30 This is especially the case when the 243 population being examined is large and, by analogy, if the findings are replicated in other 244 studies. A trial with good internal validity is likely to have true results for the population with 245 the characteristics being studied; in other words, any effect detected is likely to be caused by the 246 treatment.12 However an RCT may produce a treatment effect estimate that may not be 247 generalisable beyond the population being studied, despite having good internal validity. 248 Conversely, an RCT with good generalisability has a treatment effect estimate which can be 249 applied more broadly. However, in order to calculate an absolute risk reduction (ARR), the 250 treatment effect estimate obtained must apply to the background population against whom the 251 ARR is to be calculated. 
252 Bradford Hill lists a number of criteria which increase our confidence that an association is 253 causal (see table 3 for these criteria as applied to the medical sciences).8 
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254
255 RCTs facilitate the comparison of treatments256
257 Due to their results likely representing the truth, RCTs can directly compare different 258 treatments head-to-head when an active comparator control is used instead of placebo. This 259 allows conclusi ns regarding relative efficacy to be made. Multiple-arm studies can be used to 260 demonstrate non-inferiority or superiority, comparing multiple treatments or dosages 261 simultaneously, and are becoming more common.31 
262 However, with an ever-increasing number of treatments, it will be impractical to carry out head-263 to-head comparisons of all treatments available. A well-conducted RCT – due to the confidence 264 that the treatment effect observed is likely to be true, because of its internal validity - can more 265 easily be incorporated into adjusted indirect comparisons, mixed treatment comparisons, meta-266 analyses and systematic reviews than OP studies. RCTs allow statistical inference to be made 267 regarding the efficacy of different interventions even when head-to-head comparison has not 268 been undertaken.32  
269
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270 Maximising the results of RCTs in pharmacoepidemiology
271
272 In this section, aspects of trial design and conduct that are aimed at maximising the validity and 273 reducing the impact of the constraints inherent to RCTs are explored.  
274 Although RCTs are preferable for assessments of efficacy, individual trial methodology must be 275 scrutinised in order to critically appraise the results, see table 4 for factors that might reduce 276 confidence in RCTs or meta-analyses combining RCT results. 
277
278 The findings of RCTs may not be generalisable 279
280 RCTs are often conducted in select groups of patients, in specialist centres, by leading experts, 281 using state-of-the-art technology for a limited period of time, so-called explanatory RCTs – 282 unrepresentative of the care that patients receiving the intervention in the community would 283 experience. While these trials are critical in establishing efficacy and preliminary safety it may 284 mean that the study results are only valid in the specific group of participants included in the 285 trial. Also, some RCTs have been criticised for using surrogate or composite endpoints which do 286 not translate into clinical benefit, or for not taking into consideration factors important to 287 patients’ well-being.33 
288 Generalisability, relates to the degree to which a treatment effect estimate can be applied to a 289 wide group of patients under ‘usual conditions’ (effectiveness/external validity - see table 5 for 290 some factors to consider when assessing generalisability). This may not apply to an RCT unless 291 steps are taken to make the study more generalisable, such as using some of the following 292 methods.33 
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293 Intention to treat analysis (ITT): means that participants are analysed in the group to which they 294 were assigned, irrespective of whether they completed the study. This can help prevent attrition 295 bias.34. Attrition bias (loss to follow-up) can threaten the internal validity of RCTs by removing 296 the benefits of randomisation, introducing the potential for bias, confounding and an imbalance 297 of the prior risk of the outcome of interest between the study groups (and also reduce the 298 study’s power). Thus, attrition bias is a form of after the event selection bias where one group 299 (or both) are no longer being representative of the condition under study.33,34 
300 ITT analysis prevents biased estimates of treatment effect due to differential drop-out between 301 treatment arms and sensitivity analyses should be presented comparing relative treatment 302 effect estimates of per protocol results (only those who fully completed the study protocol) to 303 ITT results.  ITT evaluation might also better reflect real-world clinical practice (increasing 304 generalisability), where patients may stop the intervention or adhere poorly to it and thus gives 305 a more realistic estimate of the treatment effect in the wider population (as these non-adherent 306 patients are accounted for) although the maximum achievable benefit may well be 307 underestimated.10,20 It is also good practice to provide the sub-group characteristics of the 308 patients who were lost to follow-up.34
309 Pragmatic RCTs: (pRCTs) aim to redress perceived problems in the generalisability of RCTs by 310 providing answers to clinical problems relevant to patients and clinicians.35 Often pRCTs aim to 311 investigate heterogeneous patient groups, may not employ placebos and use outcome measures 312 which might include return to work, reduction in general practitioner visits and quality of life, in 313 addition to outcomes related to efficacy.35  An example of a pRCT is the Salford Lung Study, 314 which randomised ~50% of the patient population in the community,  and demonstrated the 315 superiority of fluticasone furoate and vilanterol over usual care in the management of COPD, the 316 results of which are broadly generalisable.36  
317 Large simple RCTs: (lsRCTs) are pRCTs but with protocols mandating only minimal data 318 collection on outcomes important to patients or care providers. They are well-suited to 
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319 assessing outcomes which are rare or have long latency, when study populations are 320 heterogeneous or when many risks need quantifying. lsRCTs minimise the complexity and 321 volume of data analysis as outcomes are measured from routine care. An example includes a 322 trial demonstrating that ziprasidone is not associated with an excess of non-suicide mortality, 323 despite being associated with QT-prolongation on the electrocardiogram.37 
324 Randomised database studies: are a specific form of lsRCT, capitalising on the data held in 325 electronic healthcare records or disease registry databases. They attempt to achieve both 326 internal and external validity although the optimal approach to important issues like participant 327 consent are still to be standardised. This type of trial is likely to become more common with the 328 increasing availability of computerised health data. An example includes a Swedish study which 329 demonstrated that thrombus aspiration prior to stenting in acute ST-elevation myocardial 330 infarction was no better than stenting alone, with similar outcomes in all sub-groups.38
331 Other approaches for improving generalisability: when combined into meta-analyses, the results of 332 many RCTs can be made more generalisable by merging and comparing the different study 333 populations investigated in the individual trials.
334
335 RCTs can be expensive and difficult to undertake336
337 RCTs can be expensive to conduct. This is in part due to the exacting standards required by the 338 study protocol to ensure internal validity and safety and also the length of time required for 339 follow-up.10 Also, the burden of regulation provided by internationally-agreed documents such 340 as the International Conference on Harmonisation of Good Medical Practice (ICH-GCP) are 341 viewed by some as an impediment to speedy research. This is because the burden of specific 342 data collection and retention standards for trials concerned with the supply of data for the 343 registration of interventions for human use. 39,40  Costs can increase further if larger groups of 344 patients are needed to power RCTs.10 In addition, in some situations, the outcome of interest 
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345 may be so far in the future that it is difficult and expensive to maintain follow-up.41 346 Furthermore, the elevated levels of monitoring, compared to routine clinical care,  in order to 347 meet regulatory requirements and data capture can add significantly to the cost burden of 348 running RCTs.42  
349 Cluster RCTs: (cRCTs) randomise at the group-level, say a clinic or hospital, rather than at the 350 individual patient-level. This type of study design can significantly reduce costs by reducing the 351 administrative burden of the trial since changes are introduced wholesale at the group-level, do 352 not require individual patient-level consent and may also be more easily deployed in emergency 353 situations. Deciding the unit of inference (whom the trial results will apply to) early is essential 354 in the study design to prevent the occurrence of ecological fallacy (drawing individual 355 conclusions from group-level data or vice versa). This type of trial has less statistical efficiency 356 than randomising an equivalent number of people at the individual-level. 43 An example of a 357 cRCT is the Randomised Evaluation of an Algorithm for Crohn's Treatment Trial, which 358 randomised gastroenterology clinics to either standard incremental therapies for disease 359 control or to early combined immunosuppression and demonstrated that there was no different 360 in primary outcome between the units of randomisation.44
361 It may be impossible to undertake an RCT in emergency situations; for example following a 362 terrorist incident or during an epidemic, where randomisation may be impractical or unethical, 363 and where there is a need to produce information quickly while at the same time minimising the 364 risk to patients and staff.45 The cRCT can help with these perceived difficulties. The 2014-2015 365 Ebola outbreak led to the design of novel approaches to undertaking RCTs. The adaptive ring 366 vaccination, open-label, cluster RCT (Ebola ‘Ça Suffit’ Trial) used to demonstrate efficacy of 367 rVSV-vectored Ebola vaccine, where immediate versus delayed vaccination was compared and 368 immediate vaccination was favoured.46 In ring vaccination, at-risk patients are identified for 369 vaccination by being contacts of a known Ebola case and had been used successfully during 370 smallpox eradication, but not before as a clinical trial methodology.47 
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371 Crossover RCTs: (xRCTs) can give greater precision of treatment effect, given the same number 372 of subjects, than a similarly sized parallel group study. xRCTs are a within-subject study design, 373 where participants are randomly exposed to an interventions in sequence (treatment A 374 followed by treatment B or vice versa), and thus act as their own controls.48 One of the 375 treatments may be placebo or an active control.  This reduces inter-subject variability (thus 376 increasing precision) but are not appropriate if there is a significant carryover effect from one of 377 the treatments, despite a washout period between treatments.48,49 xRCTs can thus increase 378 study power but cannot be employed for conditions with an acute natural history nor 379 investigate treatments that provide a cure rather than respite.48 For example, an xRCT was used 380 to investigate sequential plasmapheresis versus sham plasmapheresis (placebo) treatment in 381 the same patients on symptom improvement in rheumatoid arthritis and failed to demonstrate 382 a difference between the treatments.50 
383 Factorial RCT: (fRCT) is another design that can assess outcomes more efficiently than separate 384 trials.51 This allows for the assessment of multiple treatments in the same population, 385 maximises study power and also provides information on interactions between treatments.51 In 386 its simplest form, a ‘2x2’ fRCT, say treatments A or B and C or D exist. This fRCT would allow the 387 comparison between treatment A and C or D, or treatment B and C or D.  An fRCT can help 388 explain which treatment is better, either alone or in combination and whether or not there is a 389 synergistic or additive effect between treatments.51,52 An fRCT was used by investigators to 390 assess whether a shortened course of N-acetylcysteine (NAC) in paracetamol intoxication was 391 associated with fewer side effects than a 21-hour course, while at the same time assessing 392 whether pre-treatment with the anti-emetic ondansetron reduced nausea and vomiting due to 393 NAC treatment. The study found that both the shortened course of NAC and ondansetron pre-394 treatment reduced nausea and vomiting independently and also additively (and that the 395 shortened course of NAC was associated with fewer anaphylactoid reactions).53  
396
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397
398
399
400 Issues related to study power and lower than expected event rate in RCTs401
402 Careful thought is given to the planning of RCTs, in particular to ensure internal validity and 403 adequate power. However, should an insufficient number of participants be recruited, more 404 participants than expected drop-out or a lower than expected event rate be observed, then the 405 trial may not have sufficient power to detect significant change or may have to continue for 406 longer than planned to yield an adequate effect estimate.54 Some of the study designs detailed 407 below can help address these issues, in addition to the advantages already described by using 408 large pRCTs and lsRCTs.
409 Multi-arm studies and adaptive clinical trials: may be superior to two-arm studies, which frequently 410 fail to demonstrate superiority.55 Patients, clinicians and regulatory authorities want to know 411 whether certain interventions are superior to those already offered as quickly as possible.55,56 412 Multi-arm superiority trials allow the direct comparison of many different treatments or 413 different treatment regimens compared to an active comparator group. They are simpler, 414 quicker and cheaper than a series of two-arm trials investigating the same and provide data for 415 direct comparison rather than many two-arm studies being compared in meta-analysis, which 416 causes difficulties in interpretation when the studies are heterogeneous.55,56 It may also be the 417 case that multi-arm trials recruit more effectively than two-arm trials, possibly since the 418 multiple arms, with different inclusion criteria, means more patients are eligible, and well-419 designed multi-arm studies may provide significant patient benefit compared to multiple two-420 armed trials.55 The ideal study design is yet to be established and the multiple arms of the study 421 may cause difficulties in the interpretation of results, particularly when arms are removed or 422 added.
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423 Adaptive clinical trials are a type of trial design, with multiple arms, which seek to address some 424 of the concerns about multi-arms studies. To-date, they have mainly been deployed in the field 425 of oncology, since their design can handle the increasingly-recognised biological heterogeneity 426 of tumours. However, they show promise in other fields such as neurological degeneration. 427 There are different forms of these trials, but all allow some form of pre-specified adaptation, 428 guided by a master protocol, to take into account evolving understanding both from within and 429 outside the adaptive trial. They aim to address the perceived deficiencies of traditional trial 430 designs, which has been described as the ‘weakest link’ in cancer therapy development now that 431 molecular understanding of tumour biology has increased.57 The STAMPEDE trial investigating 432 treatment alternatives for advanced prostate cancer is one example of an adaptive, multi-arm, 433 multi-stage platform trial.58 However, the multiple comparisons between arms, particularly if 434 new treatment arms are added or removed, and the necessity to undertake repeated interim 435 analyses make these trials extremely complicated to analyse and interpret, as the multiple 436 comparisons increase the likelihood that a positive finding is significantly different by chance 437 alone if the multiple comparisons are not accounted for.56,59 
438 In basket trials, eligibility is determined by a master protocol often defined by the presence of a 439 molecular alternation rather than a specific tumour site. Each basket represents a molecularly-440 defined sub-trial (drug-mutation pair testing) with matched therapy or control. In umbrella 441 trials a single class or type of tumour is molecularly screened and assigned to sub-trials in light 442 of these results, where the molecular signature refines rather than defines inclusion (compare 443 with basket trials, where inclusion is defined by the molecular signature). Platform trials, have a 444 common control arm but many different experimental arms that enter or exit the trial as 445 effectiveness or futility are demonstrated (often according to Bayesian decision-making rules). 446 Adaptive randomisation, where patients with a particular molecular signature are preferentially 447 enrolled into the trial arms that show the most promise, may also be a feature.57
448
Page 21 of 70
British Pharmacological Society
British Journal of Clinical Pharmacology
British Journal of Clinical Pharm
acology
21
449 Stopping after pre-specified number of events: some trial designs, particularly when assessing 450 event-based outcomes, power the trial in terms of a minimum number of primary outcome 451 events to be observed, rather than pre-specifying the number of participants to be recruited or 452 the length of time under observation (although event rate is influenced by these two latter 453 parameters).  This may increase trial efficiency by being able to declare a treatment effect as 454 significant on the basis of an observed difference in event rates between trial arms, without 455 having to wait for a pre-specified number of participants to be enrolled or for a specific length of 456 time to have elapsed. This type of design allows for flexibility should the event rate assumptions 457 in the trial design be greater than the number of events observed in practice, which would 458 otherwise result in the trial being under-powered. The cardiovascular outcome trial examining 459 canagliflozin for the treatment of type 2 diabetes (CANVAS programme) adopted this approach 460 to demonstrate that canagliflozin reduced the number of major cardiovascular outcome events 461 compared to placebo.60
462
463 The advantages of pre-specifying sub-group analysis464
465 RCTs often report results with regards to sub-groups differing from each other in baseline traits. 466 Trial populations are often heterogenous, which raises the question of whether effects observed 467 are true for all of the patients regardless of their baseline characteristics.61,62  If conducted 468 appropriately, sub-group analysis can be illuminating, increasing generalisability, and impacting 469 positively on patient care through improved clinical decision-making.61 However, if sub-group 470 analysis is performed poorly, or indeed not reported, it can be misleading.61,62 Pre-planned sub-471 group analysis forms a key part in all the published criteria designed to help readers decide 472 whether the sub-group effect is real and is also encouraged in CONSORT.23,61 However, 473 systematic reviews have shown that reported sub-group analyses are seldom pre-specified and 474 there is a recognition that uncontrolled flexibility in the analysis of data carries a real risk of 
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475 false positive findings.61–64 If multiple assumptions are tested in sub-group analysis the 476 likelihood of a falsely significant result by chance alone increases.65 Although unscheduled sub-477 group analysis, labelled as such, may have a role in hypothesis-generation for subsequent trials, 478 statistically inferential approaches to sub-group analysis should be limited to small numbers of 479 pre-specified sub-groups underpinned by sound biological evidence to limit the reporting of 480 false positive effects.66 
481
482 The conflicting tensions in stopping trials early483
484 A complex problem is the early termination of RCTs due to beneficial effects becoming apparent, 485 where there is a tension between obtaining a true estimate of the treatment effect and denying 486 potential users a beneficial new treatment. When a trial is stopped early its internal validity is 487 compromised. It has been suggested that a trial stopped early for beneficial reasons may over-488 estimate the treatment effect because of the following: the decision to stop trials early requires 489 that data be analysed on multiple occasions; probability theory means that the more times the 490 data are analysed, the more likely the data will yield a ‘random high’ leading to the trial being 491 stopped (which would not occur if the reading were not ‘high’).30,65,67,68 Stopping trials early also 492 reduces the likelihood of adverse effects being detected as there is less time for these to 493 accumulate. Methods such as ‘increasing nominal significance’ for each analysis (e.g. the 494 O’Brien-Flemming method), which raise the threshold for stopping at interim analysis, can 495 lessen the risk of ‘random highs’ leading to trial termination by raising the threshold for this to 496 happen and should always be pre-specified in the SAP.69
497 Trials may also be stopped early for futility, which is the inability of a clinical trial to meet its 498 objectives.70 On the one hand stopping trials early for futility protects participants from being 499 exposed to ineffective treatment and can save resources to be spent of more encouraging 500 research. On the other hand, stopping for futility may leave secondary research questions 
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501 unanswered and trials that fail conventional significance testing may still be consistent with a 502 probable positive effect and contribute to the total evidence (in meta-analysis).71 Futility rules 503 must be considered before starting a trial and always be included in the SAP although it may not 504 be clear a priori how to choose the most appropriate stopping boundary. Indeed, many trials are 505 continued to their conclusion unless there is clear evidence of harm. Various statistical methods 506 exist for assessing futility including conditional rules that attempt to calculate the ultimate 507 likelihood of success. Some of these may be unduly influenced by early participants in the 508 trial.70–72 The problem of stopping trials early for futility risks the opposite effect to stopping 509 trials early for benefit, where a random high causes the trial to be terminated. In stopping for 510 futility, early results may represent ‘random lows’ which cause the illusion of no effect leading 511 to the trial being stopped, when in fact, had more information been gathered this ‘no effect 512 signal’ would disappear. 
513
514 Assessment of low frequency or long-term harms515
516 RCTs are not often powered to detect harms that occur infrequently or that only develop a 517 considerable time after exposure.73 Indeed, RCTs do not often identify a pre-defined hypothesis 518 for harms, which contrasts with the usually reported pre-specified hypothesis for efficacy.73 In 519 addition, in explanatory RCTs, due to their strict inclusion and exclusion criteria, patients at the 520 highest risk of being harmed are often excluded (e.g. older patients, those with multiple 521 comorbidities, children), although they may become the main users of the treatment if 522 licensed.73 Furthermore, in longer-term, larger RCTs it can be challenging to distinguish harms 523 which are caused by the treatment (iatrogenic) from those which are ‘inter-current and non-524 causal or just random error’.65 It should be noted that it is recognised that rare harms may not 525 become apparent until after a therapy has been licensed and table 6 illustrates the number of 526 patients to be observed to detect a given adverse event rate. In meta-analysis or systematic 
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527 reviews, conclusions about harms may also be misleading if the available data are affected by 528 publication bias.73     
529 While it is important to consider the ITT effect estimate when examining efficacy of an 530 intervention, it is important to note that, for safety evaluation, on-treatment (and per protocol) 531 analyses should be considered. This is because any harms caused by an intervention are more 532 likely to occur in those exposed to the treatment than those who are not.  
Page 25 of 70
British Pharmacological Society
British Journal of Clinical Pharmacology
British Journal of Clinical Pharm
acology
25
534 Observational Pharmacoepidemiology
535 Observational studies (see table 1 for brief description of study types) include cohort, case-536 control and cross-sectional studies.74 Cohort studies can be prospective or retrospective, with 537 individuals exposed to an intervention identified, compared to non-exposed individuals, and 538 any difference noted in the event rate over time.74 Case-control studies are retrospective. Cases 539 are identified after an event has occurred, compared to similar controls in whom the event has 540 not occurred and any differences in exposure established retrospectively.74 Cross-sectional 541 studies look at the prevalence of a disease at a specific time point and may use historical data to 542 establish exposure.74 
543 The key difference between these types of study and an RCT is that, in OP studies, the 544 intervention is selected for/by a patient, or the patient is selected on the basis of having been 545 exposed to the intervention, rather than the intervention being allocated randomly.74 This 546 makes it conceptually more difficult to attribute an outcome to a particular treatment and also 547 introduces the potential that biases or confounding account for any differences observed.74 In 548 particular, an extremely challenging problem in OP is allocation bias. In this bias, patients 549 assigned a therapy are different from patients not assigned the therapy (e.g. more severely 550 unwell participants treated more often with the intervention compared to less severely unwell 551 patients) meaning the any difference in treatment effect observed may be due to this difference 552 between patients and not the treatment. Also, the sensitivity and specificity of the outcome 553 measures are often unknown, so it is unclear whether all outcome data have been captured and 554 in what depth of detail, which leads to information bias. 
555 Despite these perceived deficiencies, OP studies (as cohort or case-control studies, but more 556 often as an adverse event reporting system e.g. the Yellow Card Scheme in the UK) are an 557 important part of post-licensing pharmacovigilance. With the increasing availability of 558 electronic health records claims databases and disease registries there is renewed interest in OP 559 studies for making inferences on the effectiveness of interventions as well as quantifying 
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560 potential harms. Although most clinician are well-trained in assessing the validity of RCTs, there 561 is less widespread knowledge of appropriate study design and statistical methods for OP. 562 However, it is vital for healthcare professionals to become versed in OP study appraisal as an 563 increasing number of these studies are likely to be published in the future, given the increasing 564 accessibility of computerised observational data and a strong push to harness these data.3,6,75 565 Clinicians will need to understand whether the study design used is appropriate given the 566 question and whether the data analysis methods are robust enough to have confidence in the 567 results. 
568 Clinical Pharmacologists are particularly well-placed to be at the forefront of robust OP study 569 production given their training in drug discovery, mechanisms of drug action, stratified 570 pharmacology and drug safety. Indeed Clinical Pharmacologists are already producing 571 informative research by conducting studies underpinned by sound biological principles such as 572 the cohort study demonstrating that paroxetine use was associated with an increased risk of 573 death in women with breast cancer treated with tamoxifen (paroxetine inhibits cytochrome 574 P450 enzyme 2D6, which in turn reduces the bioactivation of tamoxifen necessary for its clinical 575 effect).76 
576 The following sections address in more detail the characteristics and strengths of OP studies in 577 and strategies to ensure their good conduct.
578
579 OP studies allow quantification of effectiveness and can have good external validity 580
581 OP studies are often said to have high external validity, in that they are conducted in the ‘real-582 world’ and often have high levels of heterogeneity in their study populations making their 583 findings more generalisable.3,12,77 An OP study might confirm an intervention as effective in a 584 heterogeneous population sample, when the intervention has previously been demonstrated as 585 efficacious in an RCT. This is especially the case when the OP study includes some similar 
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586 participants to the RCT demonstrating efficacy and if the treatment effect detected in this sub-587 group of the OP study is in the same direction and order of magnitude as that reported in an 588 RCT.77 As such, OP studies can confirm and broaden the findings of RCTs to a wider 589 population.78 
590 STROBE: STrengthening the Reporting of OBservational studies in Epidemiology, aims to 591 ‘reduce the incomplete and inadequate reporting’ of data in observational studies, ‘which 592 hamper the assessment of strengths and weaknesses of the studies reported in the medical 593 literature’ and to ‘improve the quality of reporting’.79 Rather like CONSORT, STROBE consists of 594 guidelines and a checklist of 22 items considered essential for good reporting.79 The current 595 guidelines date from 2009, which is the first iteration and remains current. They cover the three 596 most commonly employed designs in observational studies: i) cohort studies, ii) case-control 597 studies and iii) cross-sectional studies.79 Also like CONSORT, adherence to STROBE may reduce 598 bias and allow the reader to ascertain whether included analyses were pre-planned or not, and 599 if not to offer an explanation as to why the analysis became necessary.79 STROBE came into 600 existence more recently than CONSORT (2007 vs. 1996) and thus there is less evidence to 601 suggest that it improves the quality of reporting although a bibliographic study found that of the 602 observational studies analysed, over 80% made appropriate use of STROBE.80 
603
604 OP studies can be carried out over a long period of time, detect rare adverse events and have lower 605 costs606
607 Observational studies can be carried out over much longer periods of time than RCTs. Indeed, 608 there are cohort studies that have been running for many decades, such as the Framingham 609 Cardiovascular Cohort Study, which has been running for over 65 years.81 This advantage of 610 time means that observational studies are able to provide important data on patients’ long-term 
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611 longitudinal experiences, particularly in the setting of chronic diseases with a natural history 612 over many years.82 
613 RCTs are often not sufficiently powered to detect adverse events that occur very infrequently. 614 For in tance, to detect a doubling of an event rate from 0.1% to 0.2%, ~50,000 participants 615 would need to be studied in an RCT to achieve an 80% power of detecting this at a p value of 616 0.05.83 The extended period over which OP studies can be undertaken and the relative ease of 617 obtaining a large enough population sample, compared to RCTs, makes OP studies suited to the 618 defining of adverse events and their incidence.82 Indeed, OP studies are an integral part of the 619 post-marketing surveillance programme of newly approved drugs (e.g. adverse event reporting 620 systems) and are occasionally mandated by regulators if there is an inconclusive safety signal in 621 pre-licensing RCTs.83 Observational studies can facilitate the detection of rare (<1/1,000) and 622 very rare (<1/10,000) adverse events and are also able to provide long-term data on an 623 intervention’s tolerability.78,84 See table 6 summarising the number of patients to be observed to 624 detect a given adverse event. 
625 Since observational studies frequently run in parallel with routine clinical care, they are often 626 associated with lower costs than RCTs.85 In addition, OP studies might employ data available 627 from clinical databases such as the Clinical Practice Research Datalink (CPRD) in England, the 628 Scottish Care Information - Diabetes Collaboration (SCI-DC) database and Health Maintenance 629 Organization Research Network (HMORN) in the United States.86–88 An ancillary benefit of these 630 lower costs is that OP studies may include much larger numbers of patients.85 Indeed, the future 631 of OP is likely to be represented in such longitudinal electronic healthcare records (disease 632 registry or insurance provider) databases. 
633
634 OP studies can provide data to justify RCTs 635
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636 OP studies often provide the evidence to justify an RCT.89  Observational studies are also often 637 used in ‘hypothesis generation’ for RCTs (see table 7 for areas which are suited to observational 638 studies). In addition, if the treatment effect detected in an OP study is very large then it is not 639 always necessary to undertake an RCT. 89 There are multiple examples of treatments becoming 640 established on the basis of observational data without confirmation in an RCT, such as, for 641 example, the treatment of type 1 diabetes mellitus with insulin.2
642
643
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644 Maximising the results of OP studies
645
646 The perceived disadvantages of observational studies in pharmacoepidemiology are discussed 647 below alongside methods available to diminish these, related to both study design and 648 methodology.
649
650 Bias and confounding make causality more difficult to establish in OP studies651
652 The non-random allocation of patients in OP studies means they are more prone to biases and 653 confounding, both known and unknown.90,91 Although there may be strategies to mitigate the 654 effects of biases, such as matching and multi-variable regression analysis, it is never possible to 655 correct the results for all of these possible influences, in particular the ones not known about 656 (see table 2 for a list of biases and their mitigation). Bradford Hill lists a number of criteria 657 which increase our confidence that an association is causal (see table 3 for these criteria as 658 applied to the medical sciences). 
659 Due to the inherent difficulty controlling for bias in OP studies, causality is more difficult to 660 establish since statistical association does not imply causality. It has been suggested that the 661 stronger the treatment effect found in OP studies the greater the support for causality and this 662 support is stronger still if the observation of association is consistent in different populations 663 and with different study designs. 65,90–92 
664
665 OP studies can lead to inflation of positive treatment effects and under-estimation/under-reportin  666
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667 The failure to use random allocation and blinding can be associated with relative increases in 668 the estimate of effects. Indeed, the distortion caused by not randomising and blinding during a 669 study has been associated with effect estimates as large or larger than the treatment effect 670 itself.16 On the other hand, meta-analyses of the treatment effects in OP studies and RCTs have 671 demonstrated that, by and large, when good quality studies are analysed, the direction and 672 magnitude is broadly similar.93–95 Nevertheless, the spectre of treatment effect over-inflation 673 hangs over OP studies and should always be borne in mind when considering their results. 
674 Many OP studies rely on data gathered through routine clinical practice. Conversely, for 675 different reasons to those just described, this means that OP studies may also be at risk of 676 under-estimation, where a patient fails to seek healthcare and thus the true incident rate of a 677 condition may not be recorded, or under-reporting, where following interaction with a 678 healthcare system the data are inadequately reported. This under-estimation is a form of non-679 differential information bias.96 
680
681 Approaches to dealing with the limitations of OP682
683 Different methods (in terms of study design, analysis or both) ave been employed to reduce 684 the effect of bias and confounding in OP, some of which are only appropriate in very specific 685 circumstances. One rule of thumb as a validation method is whether, within the OP study, a 686 group of subjects meeting the inclusion and exclusion criteria of a published RCT exploring the 687 effect of the same drug can be discerned. If it can be demonstrated that the patients in this sub-688 group have a treatment effect detected that is in the same direction and of the same order of 689 magnitude as that found in the RCT, then this increases confidence that the treatment effect in 690 the larger, more heterogeneous group of patients is robust. 
691
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692 Study design and analysis methods to reduce bias and confounding in OP693
694 Incident-user design: is a cohort study design aimed at reducing allocation bias, where incident-695 users (new users) of a drug for a particular indication are compared to incident-users of a 696 different drug (controls) for the same indication. This assumes that both users and controls have 697 been identified by clinical staff as benefitting from a new prescription and makes users and 698 controls more similar, particularly in characteristics which may not be observable.97 However, 699 this does not always mean that incident-users and their controls are identical – for instance 700 clinicians may avoid prescribing newly licensed drugs to frail elderly patients, sticking instead 701 to drugs they are more familiar with using in this group. In this case the users and controls 702 would cease to be as similar. Incident-user design also means precluding prevalent-users 703 (longer-term users) from the study, reducing sample size and losing potentially valuable 704 information. This design can be modified for the investigation of second- or third-line 705 treatments by examining those that switch/add treatment for the same indication, as this 706 switching/adding is not a random event, but rather influenced by disease worsening or a side 707 effect again believed to improve comparability between ‘switchers’.97 
708 Natural experiments: are alternatives to RCTs which utilise naturally occurring circumstances to 709 separate variables that usually associate together in a before and after cohort study.63 One 710 example is universal exposure to avoid selection and allocation bias, where the exposure occurs 711 in total populations rather than through choice, and thus allows comparisons to be made 712 between exposed and unexposed populations and causal inferences to be made.98 This was the 713 case in Japan, when use of the measles, mumps and rubella (MMR) vaccine abruptly stopped 714 due to concerns about cases of aseptic meningitis, perhaps caused by the particular strain of 715 mumps virus used to make the Japanese vaccine.  This allowed the exploration of whether the 716 MMR vaccine was associated with regressive autism, when concerns about this association 717 surfaced a number of years later. Here, analysis of the Japanese population before and after the 
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718 cessation of widespread MMR use found no link between MMR and regressive autism.99 Another 719 example of natural experiment, devised as an alternative to RCTs, albeit applicable in limited 720 circumstances, is regression discontinuity design. This uses a pre-determined ‘assignment 721 variable’ (e.g. CD4 count in deciding whether to start anti-retroviral treatment in human 722 immunodeficiency virus infection) with a strict cut-off, above or below which an intervention is 723 assigned, and assumes that there will be little difference in subjects marginally over or under 724 the asymptotic cut-off.98 Assignment to intervention cannot be caused by the intervention but 725 does require all participants to belong to the same population. The groups are then compared 726 by observing the differences in subjects close to the asymptotic cut-off. The effect is measured 727 by discontinuity from regression, which has been demonstrated mathematically to yield an 728 unbiased estimate of a causal effect.98 
729 Propensity scores: aim to provide less biased estimates of treatment effect and can be used for 730 matching exposed and unexposed participants in a case-control study or to exclude non-731 overlapping data from analysis on the basis of an understanding of co-variates that affect the 732 condition being studied.100 They do so by attempting to correct for the non-balanced 733 distribution of characteristics between the exposed and unexposed groups and are more 734 statistically efficient than multi-variable regression models traditionally used to control for 735 known confounders in OP studies.100 However, like multi-variable regression, propensity scores 736 can only correct for known confounders rather than all confounders but unlike multi-variable 737 regression the sensitivity of propensity scores for unknown confounders can be estimated and 738 reported.100 In order to develop an effective propensity score a thorough understanding of the 739 co-variates (i.e. the biology) is necessary for them to be included in the model.100 
740 Focussing on dose-response relationship: one of Bradford Hill’s criteria for causality is the 741 presence of a dose-response relationship, where dose can be considered in terms of single daily 742 dose and also as cumulative dose exposure over time. Thus one might expect, for example, to 743 see a larger treatment effect in those exposed to a bigger single dose of an intervention (lower 
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744 blood pressure with higher dose of antihypertensive) and more adverse events occurring with a 745 larger cumulative dose (more lung cancer with greater cumulative cigarette exposure). OP 746 cohort studies have focussed inferences on the cumulative dose-response effect, such as in 747 demonstrating that pioglitazone is not associated with an increased risk of bladder cancer.101 748 Using a two-time updated exposure term, one of ever-/never-exposure and another of 749 cumulative exposure has been shown mathematically to remove the allocation bias from the 750 cumulative exposure term and provide a more reliable treatment effect estimate based on the 751 cumulative exposure term.102 
752 Instrumental variable analysis: can be applied to non-randomised studies to control for 753 unmeasured confounding and has been used in OP cohort studies.103 The method is under-754 pinned by an ‘instrument’, which is linked to the treatment, but not directly or indirectly linked 755 to the outcome except via the treatment being investigated. The challenge with such an 756 approach is the identification of an instrument that must meet the following assumptions. First, 757 the instrument should affect treatment allocation. Second, it should be a feature that is 758 randomly assigned. Third, it should be associated with the outcome only via the treatment.103,104 759 A good example to illustrate this might be differences between hospital formularies. In this case, 760 the treatment’s accessibility depends on it being included in a particular hospital’s formulary, 761 satisfying the first assumption. Although patients are not randomly allocated to hospitals, it 762 might be acceptable to assume that, in general, patients do not present to a hospital due to 763 knowledge of its formulary, satisfying the second assumption. Finally, so long as the hospital’s 764 formulary is not associated with other practices, such as quality-of-care for instance, the 765 instrument can be thought to affect outcome only via the treatment itself, satisfying the third 766 assumption.103,104
767 This means that in theory, by making these assumptions and collecting data on the instrument, 768 it is possible to make treatment effect estimates on outcome without having to adjust for 769 confounders.103,104 
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770 Case cross-over design of case-control studies: is a within-subject study design (compare with 771 xRCT) attractive to OP, albeit appropriate only in specific circumstances. A comparison is made 772 between the event time-window and the control time-window in terms of exposure. The within-773 patient control acts to block the effect of unmeasured between-patient time-invariant 774 confounders without the need for these to be measured and prevents selection bias (as users 775 are compared to themselves). However, this type of study design requires certain assumptions 776 to be met in order to give valid results. First, the exposure must be short-lived and the outcome 777 acute. Second, the risk associated with the exposure must rise and fall rapidly. These 778 assumptions mean that the investigation of chronic diseases with long-term therapy is 779 unsuitable with this type of study. 105–107
780 Although in theory a case-cross over design could be used to investigate treatment effect, it has 781 more often been used to assess potential harms, such as demonstrating that recent vaccination 782 does not appear to raise the risk of multiple sclerosis relapse.108 Importantly, this type of study 783 design cannot account for time-varying within-patient confounders, such as changes to body 784 mass index or smoking status. It also cannot be deployed when rates of drug exposure change 785 across the time period being investigated, by, for instance, a new drug with the same indication 786 being released. The case-crossover design is also sensitive to misspecification of the exposure 787 window (see risk window bias) and if the drug is available over-the-counter, non-prescribed 788 doses would be omitted from the patient’s prescribing record leading to information bias. This 789 study design is also prone to recall bias, when patients’ recollections are used to define 790 exposure rather than more objective measures, such as prescriptions.105–107
791 Partial blinding: Partial blinding involves the blinding of some aspects of an OP study (or indeed 792 an RCT), for example observer blinding; although most OP studies by their very nature do not 793 utilise randomisation, it is still possible to employ some form of blinding. The preferred 794 technique is to separate the extraction of exposure information from outcome information.109 
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795 The published report should explain who was blinded and who was not as this helps with 796 critical appraisal.109  
797
798 Missing data799
800 Although missing data can occur in both RCTs and OP studies, RCTs often include protocols that 801 go to great lengths to reduce this phenomenon. The collection of complete data may prove more 802 challenging in OP studies, where data is collected through routine clinical practice. Missing data 803 can lead to biased estimates particularly if it is not missing at random. There are a number of 804 techniques detailed in table 8 to handle missing data, although it remains the case that the best 805 way to deal with missing data is to prevent it from happening in the first place.110  
806
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807 Some specific biases in OP 
808
809 The subsequent paragraphs give details about some specific biases in OP to be aware of:
810 Protopathic bias: occurs when the prescription of a treatment is caused by the symptoms of an 811 undiagnosed condition. An example would be pancreatic cancer causing diabetes, leading to the 812 prescription of an anti-diabetic drug. It may then appear as if the drug had caused the 813 pancreatic cancer, when in fact the cancer had caused the indication for the drug – it is a form of 814 reverse causality.111 This bias may be detected in sensitivity analysis by comparing lag times of 815 differing length from the first date of exposure to the development of the outcome.112 
816 Surveillance bias in OP studies: or detection bias, is a differential (non-random) information bias, 817 where one group of patients is more likely to have the outcome (or symptom associated with 818 the outcome) diagnosed because of increased surveillance, screening or testing for the outcome. 819 An example might be the use of ultra-sound Doppler (USS-D) for the diagnosis of deep-vein 820 thrombosis (DVT) following trauma. Centres routinely screening all trauma patients for DVT are 821 likely to have a higher rate of DVT diagnosis (and consequently treatment) than centres 822 employing a symptom-, or risk score-based approach to USS-D in trauma patients.113  This bias 823 can be reduced by employing an unexposed comparison group with a similar pre-test 824 probability of being screened, using outcomes thought to be diagnosed equally between the 825 groups or adjusting for the differential detection rate in the analysis.29
826
827 Time-related biases in OP studies828
829 Immortal time bias: is often introduced into OP studies by the definition of exposure or by the 830 subsequent analysis. This is an important misclassification bias, a type of information bias. It 
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831 refers to a period of follow-up time between cohort entry and first drug exposure when the 832 outcome of interest could not have occurred. Misclassification of the pre-exposure person-time 833 as exposed or simply not counting the pre-exposure person-time leads to this bias, where the 834 effect estimate is mistakenly skewed towards the treatment group. This bias is remedied by 835 ensuring the pre-exposure time is counted, classified and analysed as unexposed person-time.114–836 116
837 Confounding by disease stage: is another form of information bias and can occur when comparing 838 first-line therapy with subsequent treatment options. Those on first-line treatment are likely to 839 be at an earlier stage of their disease compared those and second- or third-line treatment. Thus 840 an outcome related to first-line therapy (and more likely to be prescribed to those with shorter 841 disease duration) might be misattributed to subsequent treatment (more likely to be prescribed 842 to those with longer disease duration), especially is there is a long lag between exposure and 843 outcome. This can be avoided by comparing treatments in patients with similar disease 844 duration/stage.117
845 Risk window bias: is specific to case-control studies. When considering, say, adverse drug 846 reactions, the risk window is the period following exposure when the risk of the outcome is in 847 excess of the background risk. In practice, the risk window can be extremely challenging to 848 define and if it is too large serves to under-estimate the risk of the adverse event. It is best 849 handled by sensitivity analysis comparing varying risk window durations.118
850
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851 Conclusions
852 Undoubtedly, OP studies and RCTs have both contributed significantly to the evidence 853 informing clinical practice. However, there is room for improvement to both types of approach.
854 Inferences based on RCT data are more likely to identify causal associations. This is because 855 RCT reduce biases and confounding, meaning the effects detected are more likely to be caused 856 by the treatment. However, RCTs do have shortcomings in relation to their external validity and 857 their ability to detect harms. Moreover, when deployed inappropriately, without an evidence-858 based hypothesis, if there is failure to follow the ITT principle or they report multiple 859 unplanned post-hoc subgroup analyses their findings may be misleading.
860 OP studies can complement the findings of RCTs and extend their results. However, caution 861 should be exercised in their interpretation since there is the risk that the results observed 862 represent bias or confounding. This is especially the case when making causal inferences from a 863 small or unexpected treatment effect. There is an urgent need to train clinicians to understand 864 robust study design and data analysis methods in OP to better appraise which studies provide 865 valid evidence and which do not. 
866 The pre-publication of study protocols and subgroup analysis alongside the adherence to 867 reporting guidelines (CONSORT and STROBE) improves quality and aids critical appraisal of 868 both study type. Also, design improvements or new variants of RCTs and OP studies may 869 provide methodological advantages and, for OP studies in particular, may improve our 870 confidence in their results. Combining evidence from both types of study in a considered and 871 balanced fashion would also benefit patients. 
872 It remains the case that, all things being equal, RCTs provide better quality evidence than OP 873 studies but the latter, when well-conducted, can provide evidence with considerable clinical 874 utility that may not be provided by RCTs.   
875
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1239
Randomised control trial
A study in which a number of similar people are randomly assigned to two (or more) groups to test an intervention. One group (or more) has the intervention and others act as a control (alternative intervention, placebo or no interventional at all). Outcomes are measured at specific times and any difference in response is measured statistically.
Observational Study
A prospective or retrospective study in which the investigator observes the natural course of events, with or without a control group. Rather than being randomly assigned, the intervention is chosen for, or by, the patient. Any difference in results is measured statistically. 
Table 1: Brief description of main study types (modified from NICE)1191240
1241
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Bias Mitigation in RCTs Mitigation in observational studies
Selection bias: occurs where individuals are more likely to be selected for a study than others, meaning that the patients included in the study are different from those who are not. 120
Randomising all patients who are eligible for inclusion who consentFlow chart (as recommended in CONSORT23) demonstrating patient characteristics not included in study, including those who don’t consentBlinding
Flow chart demonstrating patient characteristics not included in study, including those who don’t consent
Allocation bias: occurs due to absence of comparability between groups in the allocation of treatment such that they differ significantly from one another by a factor other than the disease or exposure under investigation. 
90,91
RandomisationBlinding Matching for a control group
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Information bias1: occurs when information is obtained differently between exposed and unexposed cases such as a flaw in measuring exposure, outcomes or co-variates with differing accuracy between groups. For continuous variables this is known as measurement error, for discrete variables classification error. 90,91
BlindingUsing standardised, validated tools to collect data
Blinding of outcome/exposureUsing standardised, validated tools to collect data
Performance bias: difference between the groups in the way that care is provided or subjects are exposed to factors other than the intervention under study.121,122
Blinding
Reporting unblinding, where this becomes necessary
Blinding of exposure
1 Differential information bias tends to exaggerate an association in either direction, where the bias functions to change the likelihood of exposed or unexposed cases being identified such that one or the other is unequally likely to be identified and recorded. Non-differential information bias, exposed and unexposed cases are affected equally, where all data might be gathered through an unreliable measure and thus test power is reduced and the association tends to be under-estimated.
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Confounding: refers to the mixture or blurring of effects. This often occurs during the statistical analysis of data gathered in observational studies, where an association is found between an exposure and an outcome but the association found is, in fact, due the observation of the effect of another, unmeasured factor. 
90,91,123
Randomisation
Blinding
Stratified randomisation
Multi-variable regression analysis, for known confounders
Attrition bias: unequal loss of participants between the groups such that they are no longer similar to one another. 121,122
ITT analysis
Flow chart demonstrating patient characteristics lost to follow-up
ITT analysis
Flow chart demonstrating patient characteristics lost to follow-up
Publication bias: when publication depends on the hypothesis being tested and the significance and direction of the effects detected. 121,122
Pre-publishing study protocols
Publishing study regardless of outcome
Pre-publishing study protocols
Publishing study regardless of outcome
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Not identifying unplanned, post-hoc sub-group analysis or, if done, not labelling them as hypothesis-generating analyses
 
Not identifying unplanned, post-hoc sub-group analysis or, if done, not labelling them as hypothesis-generating analyses
Table 2: Major biases and how they can be mitigated in RCTs and observational studies; see https://catalogofbias.org/biases/ for further detail about bias1242
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Strength of the association The stronger the association, the more likely the effect is causal
Consistency Reproducibility
Specificity A specific exposure gives rise to a specific outcome
Temporality The exposure must precede the outcome
Biological gradient A dose-response relationship; the greater the exposure the larger the effect
Plausibility Consistent with scientific understanding
Coherence Coherent with other theories
Experiment The outcome can be altered, improved or abolished by experiment – ‘here the strongest support for causation can be 
revealed’8  
Table 3: Bradford Hill’s criteria for causality as applied to medical sciences 81243
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1244
Study limitations (risk of bias) 124 Failure to conceal allocationFailure to blindLoss to follow-upFailure to consider intent-to-treat principleStopping early for benefitUse of unvalidated outcome measuresCarry-over effects in cross-over trialsRecruitment bias in cluster-randomised trials (if those recruiting participants know the participants’ allocation, even when allocation of clusters has been adequately concealed)  
Inconsistency of results 125 Point estimates vary widely across studiesConfidence intervals show minimal or no overlapThe statistical test for heterogeneity shows a low 
p-valueI2, a statistical test for heterogeneity, is large
Indirectness of evidence 126 Differences in populationsDifferences in interventionsDifferences in outcomesIndirect comparisons
Imprecision (random error) 127 Insufficient sample sizeLow event rateConfidence interval overlaps no effect
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Reporting bias 124,128 Publication bias: consider especially when only a small number of commercially funded trials availableSelective reporting bias: consider when there is non-publication of original study protocol
Table 4: Factors which might reduce confidence in an RCT, either when considered alone or when 
compared in meta-analysis 1291245
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Examples
Setting of the trial Country
Healthcare system/standard of care
Selection of patients Inclusion/exclusion criteria
Run-in periods, where non-tolerant patients are excluded
Characteristics of randomised patients Baseline characteristics
Underlying homogeneity of pathology Presence of comorbidities 
Differences between trial protocol and 
routine practice
Prohibition of non-trial treatments
Timing of treatment in disease course
Outcome measures and follow-up Surrogate outcome measures
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Use of patient-centred measures
Relevance of composite endpoints
Adverse effects of treatment Rates of discontinuation
Completeness of reporting
Exclusion of patients at risk of adverse outcomes
Table 5: Factors to consider when assessing generalisability 331246
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1247
1248 Table 6: Number of patients to be observed to detect a given adverse event, modified from 130 
1249
1250
Prospective evaluation of patient population and disease characteristics
Assessment and comparison of costs and effectiveness associated with diagnostics
Investigation of adherence to guidelines
Post-marketing surveillance
Expected incidence of adverse drug reaction Number of patients to be observed to 
detect:
1 event 2 events 3 events
1:100 300 480 650
1:200 600 960 1,300
1:1,000 3,000 4,800 6,500
1:2,000 6,000 9,600 13,000
1:10,000 30,000 48,000 65,000
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Detection of responsive sub-groups
Characterisation of risk factors and levels of risk
Identification of relevant sources of uncertainty
Cost evaluation
Formation of hypotheses to be tested in subsequent experiments
Table 7: Particular areas suited to the use of observational studies1311251
1252
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Method Description
Listwise/case 
deletion
 Simply omits the subjects in whom the data are absent. If the missing data occur randomly, then this method produces unbiased results. However, data points are often not missing at random, and in this case listwise deletion will lead to biased estimates of treatment effect. 
Pairwise 
deletion
 Omits information only when data testing a particular assumption are missing; if it is missing from elsewhere existing values are used instead. This may lead to modelling problems where sample sizes and standard errors of co-variates differ from one another. 
Mean 
substitution
 The missing value of a variable is replaced by its mean value from other subjects. This method gains no new information (as it is created from information that exists already), and leads to bias when the data are not missing at random. This is generally not an accepted approach. 
Regression 
imputation
 Uses regression modelling to estimate missing values, but like mean substitution adds to no information.
Last observation 
carried forward
 Replaces absent data with the last recorded value for all missing data points. Although this approach is simple, it under-estimates intra-subject variability and gives rise to an illusion of precision. 
Maximum 
likelihood 
modelling
 Assumes that the data present all arise from a multi-variate normal distribution. If there are few missing data, the absent data points can be estimated by using the conditional distribution of other variables. 
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Expectation 
maximisation
 Utilises maximum likelihood modelling to create an entirely new (modelled) dataset based on all the available information. The process is iterative and stops when the new dataset is stable. This approach is computer intensive, especially if there are many missing data, and tends to underestimate standard errors and thus overestimate precision. 
Multiple 
imputation
 Replaces missing data with a range of plausible values representing the natural variability of values. A model is run, substituting each value in the range for each missing data point and a standard statistical analysis is on each iteration. Summary statistics are created by combining the statistic from each model run and is robust as it retains the variability and uncertainty of the missing data. 
Sensitivity 
analysis 
 Is an analysis that aims to characterise how uncertainty in the output can be attributed to uncertainty in the input. All methods dealing with missing data should be subjected to this form of analysis, by comparing effect estimates with and without these missing data and then to the method used to handle the missing data. 1253 Table 8: Examples of various methods employed to handle missing data, modified from 110
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